Table 2 Summary of CAR-T toxicities in patients with R/R EN LBCL.

From: Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

Variable

N = 218 (%)

CRS of any grade

159 (73)

Grades 1–2

147 (67)

Grades ≥3

12 (6)

Median duration of CRS in days (range)

4 (0-57)

ICANS of any grade

81 (37)

Grades 1–2

40 (18)

Grades ≥3

41 (19)

Median duration of ICANS in days (range)

5 (0-188)

Prolonged PRBC transfusion needs (>28 days)

39 (19)

Prolonged platelet transfusion needs (>28 days)

42 (20)

Prolonged filgrastim needs (>28 days)

75 (36)

Secondary malignancy after CAR-T

5 (3)

  1. CAR-T Chimeric antigen receptor T-cell therapy, CRS cytokine release syndrome, EN Extranodal, ICANS Immune effector cell-associated neurotoxicity syndrome, LBCL Large B-cell lymphoma, PRBC packed red blood cells, R/R Relapsed/refractory.
Back to article page